Back

Percutaneous coronary intervention of in-stent restenosis: A three-arm analysis from SWEDEHEART

30 August 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Challenges in coronary artery disease Revascularisation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Sacharias Von Koch

Skane University Hospital, Lund (Sweden)

6 More presentations in this session

Presentation thumbnail
Revascularisation after discharge in patients with acute myocardial infarction complicated by cardiogenic shock
Mr M. Bjerg Andersen (Hilleroed, DK)
Abstract Slides Video
Presentation thumbnail
Long-term prognostic value of microvascular obstruction by cardiac magnetic resonance in ST-segment elevation myocardial infarction
Ms R. Amier (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Long-term outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in women with severe coronary artery disease
Doctor K. An (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Comparative outcomes of drug-coated balloon angioplasty versus second-generation drug-eluting stent for in-stent restenosis: a real-world data analysis
Doctor J. Krefting (Munich, DE)
Abstract Slides Video
Presentation thumbnail
In-hospital outcomes of acute myocardial infarction patients without standard modifiable cardiovascular risk factors across varying body mass index
Miss Y. Yang (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Challenges in coronary artery disease

The Event

Event poster

ESC Congress 2024

30 August 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Comparative outcomes of drug-coated balloon angioplasty versus second-generation drug-eluting stent for in-stent restenosis: a real-world data analysis
thumbnail
Congress Session
Strategies and outcomes in in-stent restenosis
thumbnail
Congress Presentation
Drug-coated ballons vs drug-eluting stent in de novo coronary lesions, a propensity-score matched cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources